randomized in the ESVEM Trial that favor prediction of drug efficacy and whether any variables operated differently within the two testing methods.
Determinants of Predicted Efficacy of Antiarrhythmic Drugs in the Electrophysiologic
Study Versus Electrocardiographic Monitoring Trial
The ESVEM Investigators
Background. The Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) study was designed to compare the accuracy of predictions of antiarrhythmic drug efficacy made by electrophysiological study (EPS) with those made by Holter monitoring (HM) combined with exercise testing. The present study describes the baseline characteristics and the response to drug efficacy tests of 486 randomized subjects.
Methods and Results. Patients with ventricular tachyarrhythmias were randomly assigned to undergo serial testing of up to six antiarrhythmic drugs by either EPS (EPS limb) or HM and exercise testing (HM limb) . Efficacy predictions were achieved in 108 of 242 patients in the EPS limb (45%) and in 188 of 244 patients (77%) in the HM limb. Left ventricular ejection fraction (LVEF) <0.25 and presence of coronary artery disease were negative correlates (p<0.10) of drug efficacy predictions in the EPS limb. In the HM limb, LVEF was the lone univariate correlate of efficacy, although it was only marginally significant (p=0.107). A multivariate model selected assessment by HM and higher LVEF as independent predictors (p<O.OS) of drug efficacy. The drug evaluation process required an actuarial median time of 25 days in the EPS limb and 10 days in the HM limb (p<0.0001).
Conclusions. 1) Drug efficacy predictions are achieved more frequently by HM than by EPS. 2) Assessment by HM and severity of left ventricular dysfunction are independent correlates of a drug efficacy prediction. 3) The duration of drug testing is considerably shorter for the HM method. (Circulation 1993; 87:323-329) KEY WORDs * electrophysiological study * Holter monitoring * tachyarrhythmia, ventricular sudden death E lectrophysiological studies (EPS)1 and ambulatory electrocardiographic (Holter) monitoring (HM) combined with exercise tests2 have been reported to identify antiarrhythmic drugs that prolong the time to arrhythmia recurrence in patients with sustained ventricular tachyarrhythmias. The probability of identifying an effective drug is influenced by a patient's clinical characteristics. [3] [4] [5] The Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Trial was a multicenter, randomized clinical study that tested the hypothesis that one of these two testing methods is more accurate in identifying individual drugs that are associated with freedom from ventricular tachyarrhythmia recurrence in individual patients.
The purpose of this analysis was to determine whether there are any clinical characteristics of patients Methods Details of the ESVEM Trial design have been published.6 In brief, patients who had been resuscitated from sudden death (SD) or had electrocardiographically documented sustained ventricular tachycardia (VT) or unmonitored syncope (with a subsequent EPS demonstrating inducible sustained monomorphic VT) were screened for enrollment. Patients with an average of at least 10 premature ventricular complexes (PVCs) per hour during 48 hours of HM and reproducibly inducible sustained ventricular tachyarrhythmias at EPS were eligible for randomization. An exercise test was performed before randomization.
Patients were allocated equally to serial drug evaluation by HM and exercise test (the HM limb) or by EPS (the EPS limb). Randomization was stratified by institution, PVC frequency, clinical arrhythmia, congestive heart failure class according to the symptom activity scale of Goldman (SAS class),7 and cardiac disease. Patients underwent testing of up to six antiarrhythmic drugs until one or none was predicted to be effective or all had been tested. Drugs known to have been ineffec-tive or to have caused adverse effects previously in individual patients were excluded. Drugs used during the course of the trial were imipramine, mexiletine, procainamide, quinidine, sotalol, pirmenol, and propafenone. Initially, the first five of these drugs were used. Later, imipramine was eliminated, and pirmenol and propafenone were added. Drugs were tested in random order.
Substantial PVC suppression (100% of runs of VT longer than 15 beats, 90% of shorter runs, 80% of pairs, and 70% of all ventricular ectopic beats) and absence of exercise-induced VT were required for a drug efficacy prediction in the HM limb, and suppression of inducibility of VT longer than 15 beats in duration was required in the EPS limb. At baseline, arrhythmia induction was performed with up to two extrastimuli at the right ventricular apex delivered at three drive cycle lengths. If VT or ventricular fibrillation (VF) was not induced, the catheter was positioned in the right ventricular outflow tract, where three extrastimuli were used. If this also failed to initiate VT or VF, the catheter was repositioned in the apex, and three extrastimuli were used there. During drug assessment, all patients were tested with a minimum of two extrastimuli at the apex. If more aggressive stimulation were required at baseline to induce tachyarrhythmia, that same step in the stimulation protocol was reached, if necessary, during all drug testing.
Upon prediction of drug efficacy, patients were discharged from the hospital for long-term follow-up. Subjects in whom no drug satisfied efficacy criteria were withdrawn from the study, but their vital status and arrhythmia recurrence status were monitored.
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Clinical Variables
Multiple clinical variables identified before initiation of the trial were included in the univariate and multivariate analyses to identify those that influenced the likelihood of a drug efficacy prediction ( Table 1) : They were age, sex, cardiac disease (coronary artery disease [CAD] versus other heart disease), previous myocardial infarction (MI), left ventricular ejection fraction (LVEF, determined by gaited radionuclide angiogram, contrast angiogram, or echocardiogram), severity of symptoms of heart failure (SAS class I versus classes II-IV), a-blocker use at the time of randomization, presenting arrhythmia (sustained VT or unmonitored syncope versus SD), PVC frequency (stratified at randomization as <30 versus .30 PVCs per hour), failure of previous antiarrhythmic therapy, and arrhythmia induced at EPS (VT versus VF).
Statistical Analysis
Baseline characteristics of patients in the two limbs were compared using Fisher's exact test for dichotomous variables, a X2 test for other categorical variables, and an independent-groups t test for age and LVEF. The association between baseline characteristics and predicted drug efficacy, stratified by limb, was assessed with the Mantel-Haenszel estimate of the odds ratio8 and the Cochran-Mantel-Haenszel general association statistic.9 Homogeneity of the odds ratios was tested The influence of baseline characteristics on predicted drug efficacy was evaluated using logistic regression analysis."1 Although LVEF and PVC frequency were dichotomized for descriptive purposes, they were used as continuous variables in the multivariate analyses. Because of the highly skewed distribution of PVC frequency, it was transformed using the natural logarithm. Univariate predictors of efficacy as well as risk factors that appeared to interact with the limb (p<0.10) were entered into a multivariate model. A step-down approach first eliminated nonsignificant (p>0.05) second-degree interactions with the limb and then eliminated nonsignificant main effects. Finally, a step-up technique was applied to each limb to check the consistency of the final model.
The number of days required for completion of drug testing was evaluated using Kaplan-Meier survival methods.12 The log-rank test was used to compare the survival functions in the EPS and HM limbs. SAS software13 was used for all statistical analyses. Results
Enrollment
Between October 1, 1985, and February 15, 1991, 2,103 patients with documented sustained VT, aborted SD, or unmonitored syncope with inducible VT were screened for enrollment (see Figure 1 ). One or more exclusion criteria were identified in 569, the most common of which were an MI within 3 weeks (n=223) 
Clinical Characteristics of Randomized Patients
The mean age of randomized patients was 65 years (see Table 1 ). The great majority of patients were men with CAD and previous MI, and three fourths presented with sustained VT. Two thirds had previously failed at least one antiarrhythmic drug trial. Most had a mean PVC frequency greater than 30/hr and inducible sustained VT. Three fourths had symptomatic congestive heart failure. The mean LVEF was 0.32. There were no statistically or clinically significant differences in patients randomized to the two limbs except for p8-blocker use (10% in the EPS limb versus 17% in the HM limb, p=0.022).
Prediction of Efficacy
Frequency of efficacy predictions was calculated on the basis of individual drug trials (Figure 2 ) and on the basis of individual patients (Figure 3 ). There were 1,281 individual antiarrhythmic drug trials (an average of 2.6 trials per patient). The relative frequency with which each individual drug was tested was similar in the two limbs. Efficacy was predicted in 307 trials (24%). In the EPS limb, there were 767 drug trials (3.2 trials per patient). Efficacy was predicted in 112 of these trials (15%). Among the 655 drug trials in which efficacy was not achieved, the trial was not completed in 212 (32%), usually because of intolerance of the drug (n=181, 85%). In the HM limb, there were 514 drug trials initiated (2.1 per patient). Efficacy was predicted in 195 (38%). The trial was not completed in 164 of 319 (51%), primarily because of drug intolerance (n = 132, 80%). Thus, HM yielded a greater frequency of effective drug trials than EPS.
There were 296 among the 486 patients who were randomized (61%) in whom antiarrhythmic drug efficacy was predicted. In nine patients, efficacy was predicted for two drugs. The second efficacy prediction resulted from a second series of drug testing that was permitted in patients in whom the first drug that was predicted to be effective had to be discontinued because of side effects within 1 month. One patient received three efficacy predictions. The first drug was discontinued because it was mistakenly thought to be ineffective, and the second was discontinued because of side effects after hospital discharge. No efficacy was predicted in 190 patients (39%), 33 (17%) of whom did not have an efficacy test in most cases because of intervening side effects.
Among the 242 subjects in the EPS limb, 108 (45%) achieved an efficacy prediction. In 134 (55%), no efficacy was predicted during serial testing. Sixteen of these 134 patients were withdrawn before a drug efficacy assessment was completed. In the HM limb, 188 of 244 patients satisfied the criteria for efficacy (77%). No efficacy was predicted in 56 (23%), among whom 17 had been withdrawn before drug testing. Thus, only 39 of 227 patients (17%) in the HM limb who underwent at least one drug efficacy assessment failed to achieve an efficacy prediction. Patients were more likely to receive a drug efficacy prediction by HM than by EPS. In the HM limb, patients who qualified for an efficacy prediction on the basis of adequate suppression of ventricular ectopy underwent exercise stress testing. Their HM efficacy prediction was rescinded if VT of more than four-beat duration occurred during exercise. This occurred in only five cases.
Univariate Correlates of Prediction of Efficacy
Clinical variables were examined to determine if they correlated (p<0.1) with a prediction of antiarrhythmic drug efficacy and if they correlated differently (p<0.1) in the two limbs (see Table 2 ). Four variables affected the likelihood of a prediction of antiarrhythmic drug efficacy.
Left ventricular ejection fraction. LVEF was dichotomized at 0.25. Higher LVEF was the only variable that significantly favored a prediction of efficacy in the overall group (p=0.011). This effect was approximately the same in the two limbs (p=0.062 in the EPS limb and p=0.107 in the HM limb).
Coronary artery disease. Patients with CAD were much less likely to achieve a drug efficacy prediction in the EPS limb than were those with other cardiac diseases (p=0.040). In the HM limb, there was a trend in the opposite direction that was not statistically sig-nificant. Thus, the odds of an efficacy prediction in the two limbs were significantly different for patients with CAD (p=0.079).
Sex. Female sex favored a prediction of efficacy in the EPS limb and inefficacy in the HM limb. Although the effect was not statistically significant in either limb, the difference between the limbs in the effect of this variable was significant (p=0.065).
PVC frequency. Lower frequency of PVCs favored drug efficacy in the EPS limb and inefficacy in the HM limb, although not significantly in either case. The differing influence of this variable was statistically significant (p=0.048).
Multivariate Correlates of Prediction of Efficacy
A multivariate model was developed to evaluate the effects of assessment method (HM versus EPS), underlying disease (CAD versus other), LVEF, sex, and PVC frequency on efficacy (see Table 3 ). The previously identified weak univariate interactions with assessment method were no longer significant in the multivariate model and were eliminated along with the main effects of CAD, sex, and PVC frequency. Only two independent correlates of efficacy were identified: assessment method and LVEF. Using this model, probabilities of an efficacy prediction can be calculated for each limb. For example, a patient with an LVEF value of 0.19 (which was the mean LVEF among patients with LVEF <0.25) has a probability of efficacy of 0.39 in the EPS limb and 0.73 in the HM limb. A patient with an LVEF of 0.38 (the mean LVEF among subjects with LVEF 20.25) has a probability of 0.48 in the EPS limb compared with 0.80 in the HM limb.
Time Required for Testing
Among patients who achieved a drug efficacy prediction, the time required was nearly identical (p=0.27) in the two limbs (Figure 4, left panel) ; the actuarial median time to an efficacy prediction from the day of randomization was 9 days in the EPS limb and 8 days in the HM limb. The duration of testing among all patients, including those in whom no drug was predicted effective, was longer (p=0.0001) in the EPS limb (Figure 4, right panel) . The median duration of testing in the EPS limb was 25 days and only 10 days in the HM limb. In both limbs, approximately 75% of all efficacy predictions were achieved by day 14. In the EPS limb, testing beyond day 23 added 14 efficacy predictions (13% of the total). In the HM limb, it added only 10 (5%). The median duration of testing among patients who ultimately did not receive an efficacy prediction was 18 days in the EPS limb and 15 days in the HM limb (p=0.270).
Discussion This study shows that HM predicts antiarrhythmic drug efficacy considerably more frequently than EPS; of course, this finding does not indicate which makes more reliable predictions.
In the study of Mitchell et al, 14 which is the only previous randomized comparison of EPS and HM, greater permissiveness of HM was also observed. An efficacy prediction was achieved in 15 of 28 subjects (54%) randomized to the EPS limb and in all 29 patients (100%) in the HM limb. We are not aware of previous randomized trials, including that of Mitchell et al, in which drug usage was strictly regimented and the sequence of drug administration was randomized, resulting in uniform application of drugs for both EPS and HM testing. Uniformity of drug usage in our study reduced the possibility of bias caused by unequal distribution of drugs tested in the two limbs.
The specific criteria used to identify efficacy can influence the frequency of efficacy predictions by HM and EPS, as previously documented. [15] [16] [17] In the ESVEM Trial, we used criteria similar to those used widely by clinicians and investigators. The frequency of efficacy predictions by EPS and HM might have been more similar if more demanding criteria had been used in the HM limb or less demanding criteria had been used in the EPS limb. However, such criteria would not have been meaningful in the context of current clinical practice.
Graboys et a12 have emphasized the importance of exercise stress testing in noninvasive prediction of antiarrhythmic drug efficacy. In our study, exercise stress test results only rarely disagreed with predictions of x2=55.3, 2 df;p=0.001. efficacy by HM. Our trial design does not allow us to determine concordance of predictions of inefficacy by exercise test and HM. The noninvasive technique used by Graboys et a12 involved virtually simultaneous application of HM and exercise testing. They did not separately categorize responses to exercise stress test and HM.2 Our data suggest that exercise testing as we applied it does not add sufficient information to HM to justify its use as a means to validate efficacy predictions by HM. Swerdlow and Peterson18 observed that among patients with ventricular tachyarrhythmias whom they screened for serial drug testing, only 4% did not have inducible sustained VT at EPS, and 17% had < 10 PVCs per hour on HM. In the study of Mitchell and colleagues,14 17% did not have inducible tachyarrhythmia and 32% had <30 PVCs per hour (and presumably fewer had <10 PVCs per hour). We found that 25% of randomization-eligible subjects did not have inducible tachyarrhythmias, 9% had <10 PVCs per hour, and an additional 2% had neither. However, our figures may underestimate the true incidences of noninducibility and infrequent ventricular ectopy because some patients may not have been screened for eligibility for this trial because of prior knowledge that they failed to satisfy EPS or HM entry criteria. In addition, some excluded patients did not undergo both EPS and HM.
Our findings are not applicable to all patients with sustained VT or aborted SD because we excluded patients without frequent PVCs or inducible tachyarrhythmia. On the basis of the figures above, we estimate that 35% of the general population with sustained ventricular tachyarrhythmias would not qualify for testing either by HM or by EPS. Noneligibility for testing by one of the methods may correlate with response rates to drugs tested by the alternate method different from those that we observed. Weeks After Randomization Some univariate correlates of efficacy predictions appeared to differ in the two limbs, but multivariate analysis did not support meaningful interactions with the limb. LVEF was the only clinical variable that exerted a significant influence on the likelihood of an efficacy prediction, and this effect was the same in both limbs.
Three previous studies have identified clinical correlates of a drug efficacy prediction by EPS testing.
Among the variables that we tested, Swerdlow and colleagues3 identified coronary disease, previous antiarrhythmic drug inefficacy, and male sex to be statistically significant negative univariate correlates of an efficacy prediction. We also found coronary disease to be significant and identified a trend for sex in the EPS limb but in the univariate model only. They did not evaluate LVEF but did find heart failure classification to be predictive. We found LVEF predictive rather than heart failure class. Schoenfeld and associates4 performed a similar analysis. They found only previous antiarrhythmic drug failure to be an independent predictor among the variables we examined. The nature of the induced ventricular tachyarrhythmia was also a predictor in their multivariate model. However, their study included a larger proportion of subjects resuscitated from out-ofhospital cardiac arrest than Swerdlow and colleagues' or ours as well as patients with unsustained VT. Spielman et al5 identified older age, lower ejection fraction, left ventricular aneurysm, and presence of coronary disease to be independent predictors of drug efficacy by EPS testing in a patient population similar to ours. We did not examine aneurysm as a predictor in our study.
Male sex was found to be a negative correlate of efficacy predictions in the study of Swerdlow et al. 3 Freedman et a119 found male sex to be the strongest independent predictor of ventricular arrhythmia inducibility in survivors of cardiac arrest, and inducibility was the strongest predictor of a poor long-term outcome. 20 We also found that female sex favored a response at EPS compared with HM, but the interaction was weak, and sex did not predict outcome in our multivariate model. There is no immediately apparent reason why women seem to fare better then men with ventricular tachyarrhythmias undergoing serial drug testing by EPS. Underlying disease could play a role in that existing measures of coronary disease may not be sufficiently sensitive and precise to establish the true extent of correlation between sex and disease. Drug selection by the EPS method required more time in comparison with the HM method. This difference was primarily a result of protracted testing in the EPS limb in patients who ultimately were unresponsive to most or all of the drugs. Although this observation might suggest that the duration of testing by EPS should be limited, we observed that testing extended beyond 23 days was nearly three times as likely to yield an efficacy prediction in the EPS limb compared with the HM limb. Nevertheless, a longer period of hospitalization increases cost and exposes the patient to potential adverse effects of additional antiarrhythmic drugs. This analysis shows that HM produces more predictions of antiarrhythmic drug efficacy than EPS. However, this finding alone does not indicate superiority of the HM testing method for identification of antiarrhythmic drug efficacy in patients with ventricular tachyarrhythmias. The accuracy of predictions by EPS and HM will be the principal determinant of their relative clinical use.
